{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:03:38Z","timestamp":1777604618699,"version":"3.51.4"},"reference-count":73,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Hepatocellular carcinoma is the most common primary liver tumor. Orthotopic liver transplant is one of the best treatment options, but its waiting list has to be considered. Bridge therapies have been introduced in order to limit this issue. The aim of this study is to evaluate if bridge therapies in advanced hepatocellular carcinoma can improve overall survival and reduce de-listing. We selected 185 articles. The search was limited to English articles involving only adult patients. These were deduplicated and articles with incomplete text or irrelevant conclusions were excluded. Sorafenib is the standard of care for advanced hepatocellular carcinoma and increases overall survival without any significant drug toxicity. However, its survival benefit is limited. The combination of transarterial chemoembolization + sorafenib, instead, delays tumor progression, although its survival benefit is still uncertain. A few studies have shown that patients undergoing transarterial chemoembolization + radiation therapy have similar or even better outcomes than those undergoing transarterial chemoembolization or sorafenib alone for rates of histopathologic complete response (89% had no residual in the explant). Also, the combined therapy of transarterial chemoembolization + radiotherapy + sorafenib was compared to the association of transarterial chemoembolization + radiotherapy and was associated with a better survival rate (24 vs. 17 months). Moreover, immunotherapy revealed new encouraging perspectives. Combination therapies showed the most encouraging results and could become the gold standard as a bridge to transplant for patients with advanced hepatocellular carcinoma.<\/jats:p>","DOI":"10.3390\/medicina60061010","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:42:03Z","timestamp":1718883723000},"page":"1010","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bridge Therapy before Liver Transplant for Advanced Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"60","author":[{"given":"Valentina","family":"Bianchi","sequence":"first","affiliation":[{"name":"Emergency Surgery and Trauma Center, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erida","family":"Nure","sequence":"additional","affiliation":[{"name":"General and Transplant Surgery, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Nesci","sequence":"additional","affiliation":[{"name":"Emergency Surgery and Trauma Center, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1355-0207","authenticated-orcid":false,"given":"Marco Maria","family":"Pascale","sequence":"additional","affiliation":[{"name":"General and Transplant Surgery, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Sganga","sequence":"additional","affiliation":[{"name":"Emergency Surgery and Trauma Center, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"},{"name":"Catholic School of Medicine \u201cAgostino Gemelli\u201d, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Agnes","sequence":"additional","affiliation":[{"name":"General and Transplant Surgery, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"},{"name":"Catholic School of Medicine \u201cAgostino Gemelli\u201d, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8820-9471","authenticated-orcid":false,"given":"Giuseppe","family":"Brisinda","sequence":"additional","affiliation":[{"name":"Emergency Surgery and Trauma Center, Department of Abdominal and Endocrine Metabolic Medical and Surgical Sciences, Fondazione Policlinico Universitario A Gemelli, IRCCS, 00168 Rome, Italy"},{"name":"Catholic School of Medicine \u201cAgostino Gemelli\u201d, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/17474124.2021.1991792","article-title":"Current epidemiology in hepatocellular carcinoma","volume":"15","author":"Konyn","year":"2021","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vitale, A., Romano, P., Cillo, U., Busti, M., Nezi, G., De Carlis, R., Ratti, F., Milana, F., Donadon, M., and Marinelli, L. (2024). Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma. JAMA Surg.","DOI":"10.1001\/jamasurg.2024.1184"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cnc.2022.04.004","article-title":"Hepatocellular Carcinoma","volume":"34","author":"Gilles","year":"2022","journal-title":"Crit. Care Nurs. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/MOT.0b013e3283465756","article-title":"Hepatocellular carcinoma and liver transplantation","volume":"16","author":"Washburn","year":"2011","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.gastro.2004.09.013","article-title":"Hepatocellular carcinoma: Recent trends in the United States","volume":"127","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.transproceed.2012.07.006","article-title":"Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma","volume":"44","author":"Garcia","year":"2012","journal-title":"Transplant. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10327","DOI":"10.3748\/wjg.v21.i36.10327","article-title":"Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system","volume":"21","author":"Han","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11648","DOI":"10.3389\/ti.2023.11648","article-title":"European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma","volume":"36","author":"Claasen","year":"2023","journal-title":"Transpl. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.3748\/wjg.v19.i43.7515","article-title":"Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation","volume":"19","author":"Pompili","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11894-000-0054-4","article-title":"Localized hepatocellular carcinoma: Therapeutic options","volume":"2","author":"Ribeiro","year":"2000","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1097\/00004836-200211002-00009","article-title":"Surgery and ablative therapy for hepatocellular carcinoma","volume":"35","author":"Cha","year":"2002","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00423-005-0552-9","article-title":"Surgical treatment of hepatocellular carcinoma in China: Surgical techniques, indications, and outcomes","volume":"390","author":"Chen","year":"2005","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: A multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1440-1746.2007.05262.x","article-title":"Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study","volume":"23","author":"Yamagiwa","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics","volume":"46","author":"Varela","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3748\/wjg.v21.i21.6518","article-title":"Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives","volume":"21","author":"Sacco","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1055-3207(02)00089-3","article-title":"Hepatic artery embolization for hepatocellular carcinoma: Technique, patient selection, and outcomes","volume":"12","author":"Ahrar","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.transproceed.2015.12.078","article-title":"Drug-Eluting Bead Transarterial Chemoembolization as Bridge Therapy for Hepatocellular Carcinoma Before Living-Donor Liver Transplantation","volume":"48","author":"Yu","year":"2016","journal-title":"Transplant. Proc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/ajg.2014.152","article-title":"Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller","volume":"109","author":"Kim","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11605-013-2440-x","article-title":"Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A","volume":"18","author":"Jin","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jvir.2015.02.004","article-title":"Comparison of transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: A propensity score analysis","volume":"26","author":"Lee","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: The BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3747\/co.21.1829","article-title":"The role of interventional radiology in the management of hepatocellular carcinoma","volume":"21","author":"Molla","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4254\/wjh.v7.i5.738","article-title":"Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives","volume":"7","author":"Mosconi","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111092","DOI":"10.1016\/j.ejrad.2023.111092","article-title":"Comparing Long-Term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial Chemoembolization: A propensity score matched study","volume":"167","author":"Zhang","year":"2023","journal-title":"Eur. J. Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, Y., Chou, B., Yalamanchili, A., Lim, S.N., Dawson, L.A., and Thomas, T.O. (2023). Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103517"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00004424-199003000-00011","article-title":"Hepatic ablation using radiofrequency electrocautery","volume":"25","author":"McGahan","year":"1990","journal-title":"Investig. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/hep.20688","article-title":"Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation","volume":"41","author":"Lu","year":"2005","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/j.1572-0241.2000.03205.x","article-title":"Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: A validated prognostic model","volume":"95","author":"Orlando","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00042737-200403000-00013","article-title":"Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency","volume":"16","author":"Huo","year":"2004","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1665-2681(19)31769-7","article-title":"Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma","volume":"8","author":"Branco","year":"2009","journal-title":"Ann. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2214\/AJR.06.0810","article-title":"Differences in ablation size in porcine kidney, liver, and lung after cryoablation using the same ablation protocol","volume":"188","author":"Permpongkosol","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archsurg.135.6.657","article-title":"Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm","volume":"135","author":"Bilchik","year":"2000","journal-title":"Arch. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.3748\/wjg.14.7170","article-title":"Laser ablation of hepatocellular carcinoma\u2014A review","volume":"14","author":"Gedroyc","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cld.2004.12.002","article-title":"A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma","volume":"9","author":"Lencioni","year":"2005","journal-title":"Clin. Liver Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/02656736.2020.1752400","article-title":"Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: A propensity score matching analysis","volume":"37","author":"Chen","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/era.09.41","article-title":"Sorafenib therapy in advanced hepatocellular carcinoma: The SHARP trial","volume":"9","author":"Rimassa","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12581","DOI":"10.3748\/wjg.v20.i35.12581","article-title":"Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma","volume":"20","author":"Yada","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.12168","article-title":"Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma","volume":"33","author":"Cho","year":"2013","journal-title":"Liver Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.bj.2020.07.001","article-title":"Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma","volume":"44","author":"Yu","year":"2021","journal-title":"Biomed. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12964-023-01355-2","article-title":"Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K\/Akt and Wnt\/beta-catenin pathways in hepatocellular carcinoma","volume":"21","author":"Seo","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.3748\/wjg.15.3664","article-title":"Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma","volume":"15","author":"Xu","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Huang, Y.K., Yen, C.L., Shiu, S.I., Lee, S.W., Chang, P.Y., Yeh, H.Z., and Lee, T.Y. (2017). Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188999"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.aohep.2021.100552","article-title":"Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus","volume":"27","author":"Zhang","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","article-title":"Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma","volume":"13","author":"Uka","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12072-011-9322-7","article-title":"Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: A propensity score matching analysis","volume":"6","author":"Lee","year":"2012","journal-title":"Hepatol. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiol.10101058","article-title":"Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival","volume":"258","author":"Chung","year":"2011","journal-title":"Radiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1440-1746.2010.06341.x","article-title":"Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?","volume":"26","author":"Yoo","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1148\/radiol.13130150","article-title":"Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: Results of propensity score analyses","volume":"269","author":"Choi","year":"2013","journal-title":"Radiology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jvir.2014.10.019","article-title":"Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score analysis","volume":"26","author":"Kim","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3748\/wjg.v27.i24.3630","article-title":"High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy","volume":"27","author":"Bauer","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13014-020-01739-5","article-title":"Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: A case series","volume":"16","author":"Wang","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e35713","DOI":"10.1097\/MD.0000000000035713","article-title":"Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","article-title":"Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00270-018-1993-1","article-title":"Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma","volume":"41","author":"Goyal","year":"2018","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.3390\/curroncol30110711","article-title":"Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)","volume":"30","author":"Bicer","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00262-021-03087-z","article-title":"PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival","volume":"71","author":"Nunez","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.dld.2012.02.014","article-title":"Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma","volume":"44","author":"Vitale","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hoffmann, K., Glimm, H., Radeleff, B., Richter, G., Heining, C., Schenkel, I., Zahlten-Hinguranage, A., Schirrmacher, P., Schmidt, J., and Buchler, M.W. (2008). Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation\u2014HeiLivCa [ISRCTN24081794]. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-349"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12029-010-9146-z","article-title":"Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma","volume":"41","author":"Welker","year":"2010","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3748\/wjg.v21.i13.3826","article-title":"Current management of hepatocellular carcinoma: An Eastern perspective","volume":"21","author":"Yim","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e0136","DOI":"10.1097\/CLD.0000000000000136","article-title":"From research to reality: The role of artificial intelligence applications in HCC care","volume":"23","author":"Wiest","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/00031348211063549","article-title":"A Model Based on Artificial Intelligence Algorithm for Monitoring Recurrence of HCC after Hepatectomy","volume":"89","author":"Sun","year":"2023","journal-title":"Am. Surg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/6\/1010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:01:41Z","timestamp":1760108501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/6\/1010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["medicina60061010"],"URL":"https:\/\/doi.org\/10.3390\/medicina60061010","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}